Skip to main content

David Charles Montefiori, PhD

Professor of Surgery
Office: Surgical Oncology Res Fac, Durham, NC 27710
Campus Mail: DUMC Box 2926 Med Ctr, Durham, NC 27710

Dr. Montefiori is Professor and Director of the Laboratory for AIDS Vaccine Research and Development in the Department of Surgery, Division of Surgical Sciences, Duke University Medical Center. His major research interests are viral immunology and AIDS vaccine development, with a special emphasis on neutralizing antibodies. One of his highest priorities is to identify immunogens that generate broadly cross-reactive neutralizing antibodies for inclusion in HIV vaccines.  Many aspects of the neutralizing antibody response are studied in his laboratory, including mechanisms of neutralization and escape, epitope diversity among genetic subtypes and geographic origins, ontogeny of broadly neutralizing antibody responses and computationally-assisted vaccine design. Over the years he has explored multiple types of assays for neutralizing antibodies and other potential antiviral antibodies, focusing on assay optimization, standardization, validation and high throughput. The scope of research covers HIV-infected individuals and nonhuman primate models of simian immunodeficiency virus (SIV) and simian-human immunodeficiency virus (SHIV) infection.  Dr. Montefiori also directs a large AIDS vaccine immune monitoring program, which operates in compliance with Good Clinical Laboratory Practice and has served as a national and international resource for standardized assessments of neutralizing antibody responses in preclinical and clinical trials of candidate AIDS vaccines since 1988. In 2002 he chaired the Antibody Laboratory Standardization Working Group that assisted in the design of the Global HIV Vaccine Enterprise Strategic Plan for HIV vaccines. He currently directs the Core Neutralizing Antibody Laboratories for the HIV Vaccine Clinical Trials Network (HVTN), the NIH Preclinical HIV-1 Vaccine Program and the Center for HIV/AIDS Vaccine Immunology- Immunogen Design (CHAVI-ID). He also directs a large Comprehensive Antibody Vaccine Immune Monitoring Consortium (CAVIMC) as part of the Bill and Melinda Gates Foundation's Collaboration for AIDS Vaccine Discovery (CAVD). He has published over 500 original research papers that have helped shape the scientific rationale for antibody-based HIV-1 vaccines.

Education and Training

  • Ph.D., Clemson University, 1982

Publications

Lévy, Yves, Christine Lacabaratz, Kim Ellefsen-Lavoie, Wolfgang Stöhr, Jean-Daniel Lelièvre, Pierre-Alexandre Bart, Odile Launay, et al. “Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial.” Plos Pathog 16, no. 6 (June 2020): e1008522. https://doi.org/10.1371/journal.ppat.1008522.

Full Text

Arunachalam, Prabhu S., Tysheena P. Charles, Vineet Joag, Venkata S. Bollimpelli, Madeleine K. D. Scott, Florian Wimmers, Samantha L. Burton, et al. “T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers.” Nat Med 26, no. 6 (June 2020): 932–40. https://doi.org/10.1038/s41591-020-0858-8.

Full Text

Felber, Barbara K., Zhongyan Lu, Xintao Hu, Antonio Valentin, Margherita Rosati, Christopher A. L. Remmel, Joshua A. Weiner, et al. “Co-immunization of DNA and Protein in the Same Anatomical Sites Induces Superior Protective Immune Responses against SHIV Challenge.” Cell Rep 31, no. 6 (May 12, 2020): 107624. https://doi.org/10.1016/j.celrep.2020.107624.

Full Text

Moodie, Zoe, Stephen R. Walsh, Fatima Laher, Lucas Maganga, Michael E. Herce, Sarita Naidoo, Mina C. Hosseinipour, et al. “Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials.” Plos Med 17, no. 5 (May 2020): e1003117. https://doi.org/10.1371/journal.pmed.1003117.

Full Text

Schifanella, Luca, Susan W. Barnett, Massimiliano Bissa, Veronica Galli, Melvin N. Doster, Monica Vaccari, Georgia D. Tomaras, et al. “Correction: ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type.” Plos Pathog 16, no. 4 (April 2020): e1008531. https://doi.org/10.1371/journal.ppat.1008531.

Full Text

Bharadwaj, Pranay, Cassidy Riekofski, Shu Lin, Michael S. Seaman, David A. Garber, David Montefiori, Marcella Sarzotti-Kelsoe, Margaret E. Ackerman, and Joshua A. Weiner. “Implementation of a three-tiered approach to identify and characterize anti-drug antibodies raised against HIV-specific broadly neutralizing antibodies.” J Immunol Methods 479 (April 2020): 112764. https://doi.org/10.1016/j.jim.2020.112764.

Full Text

Nguyen, Dung N., Richard L. Redman, Satoru Horiya, Jennifer K. Bailey, Bokai Xu, Robyn L. Stanfield, J Sebastian Temme, et al. “The Impact of Sustained Immunization Regimens on the Antibody Response to Oligomannose Glycans.” Acs Chem Biol 15, no. 3 (March 20, 2020): 789–98. https://doi.org/10.1021/acschembio.0c00053.

Full Text

Martinez, David R., Joshua J. Tu, Amit Kumar, Jesse F. Mangold, Riley J. Mangan, Ria Goswami, Elena E. Giorgi, et al. “Maternal Broadly Neutralizing Antibodies Can Select for Neutralization-Resistant, Infant-Transmitted/Founder HIV Variants.” Mbio 11, no. 2 (March 10, 2020). https://doi.org/10.1128/mBio.00176-20.

Full Text

Gorini, Giacomo, Slim Fourati, Monica Vaccari, Mohammad Arif Rahman, Shari N. Gordon, Dallas R. Brown, Lynn Law, et al. “Engagement of monocytes, NK cells, and CD4+ Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIVmac251 vaginal acquisition.” Plos Pathog 16, no. 3 (March 2020): e1008377. https://doi.org/10.1371/journal.ppat.1008377.

Full Text

Silva de Castro, Isabela, Shari N. Gordon, Jun Liu, Massimiliano Bissa, Katherine McKinnon, Hung V. Trinh, Melvin N. Doster, et al. “Expression of CD40L by the ALVAC-Simian Immunodeficiency Virus Vector Abrogates T Cell Responses in Macaques.” J Virol 94, no. 6 (February 28, 2020). https://doi.org/10.1128/JVI.01933-19.

Full Text

Pages